
## Erica Rurali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5885052/publications.pdf Version: 2024-02-01



FRICA RUDALL

#	Article	IF	CITATIONS
1	Novel Targets for Old and Diseased Hearts. International Journal of Molecular Sciences, 2022, 23, 6627.	1.8	0
2	Diabetes Induces a Transcriptional Signature in Bone Marrow–Derived CD34+ Hematopoietic Stem Cells Predictive of Their Progeny Dysfunction. International Journal of Molecular Sciences, 2021, 22, 1423.	1.8	5
3	Son of a Lesser God: The Case of Cell Therapy for Refractory Angina. Frontiers in Cardiovascular Medicine, 2021, 8, 709795.	1.1	2
4	Cyclophilin A/EMMPRIN Axis Is Involved in Pro-Fibrotic Processes Associated with Thoracic Aortic Aneurysm of Marfan Syndrome Patients. Cells, 2020, 9, 154.	1.8	11
5	New Strategies to Enhance Myocardial Regeneration: Expectations and Challenges from Preclinical Evidence. Current Stem Cell Research and Therapy, 2020, 15, 696-710.	0.6	6
6	Sensitive and quantitative method to evaluate DNA methylation of the positive regulatory domains (PRDI, PRDII) and cAMP response element (CRE) in human endothelial nitric oxide synthase promoter. Nitric Oxide - Biology and Chemistry, 2019, 92, 41-48.	1.2	0
7	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	1.1	11
8	Soluble EMMPRIN levels discriminate aortic ectasia in Marfan syndrome patients. Theranostics, 2019, 9, 2224-2234.	4.6	9
9	Cyclophilin A in Arrhythmogenic Cardiomyopathy Cardiac Remodeling. International Journal of Molecular Sciences, 2019, 20, 2403.	1.8	4
10	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.3	136
11	Cardiac fibrosis in regenerative medicine: destroy to rebuild. Journal of Thoracic Disease, 2018, 10, S2376-S2389.	0.6	15
12	Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO). Stem Cell Research and Therapy, 2018, 9, 235.	2.4	14
13	Precise Therapy for Thoracic Aortic Aneurysm in Marfan Syndrome: A Puzzle Nearing Its Solution. Progress in Cardiovascular Diseases, 2018, 61, 328-335.	1.6	15
14	Vascular smooth muscle cells in Marfan syndrome aneurysm: the broken bricks in the aortic wall. Cellular and Molecular Life Sciences, 2017, 74, 267-277.	2.4	41
15	BM ageing: Implication for cell therapy with EPCs. Mechanisms of Ageing and Development, 2016, 159, 4-13.	2.2	14
16	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	2.1	25
17	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	2.2	12
18	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	3.0	308

#	Article	IF	CITATIONS
19	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. Diabetes, 2013, 62, 3599-3609.	0.3	25
20	Hereditary ADAMTS 13 deficiency presenting as recurrent acute kidney injury. Indian Journal of Nephrology, 2012, 22, 298.	0.2	4
21	Congenital thrombotic thrombocytopenic purpura (cTTP) with two novel mutations. Pediatric Blood and Cancer, 2012, 59, 1296-1298.	0.8	6